Remus Pharmaceuticals Ltd (Pharma - Others) — fundamental analysis, earnings data, and key metrics. PE: 24.1. ROE: 14.0%. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on Q2 FY26 earnings • Updated Apr 18, 2026
What: B2C Revenue Mix: 13%
Impact: Targeting 8-10% PAT margin
“this year itself these 6 months there is a 9% growth on our B2C segment. So, last year was 4% as we speak right now 30th September is 13%.”
What: New Approvals: 37
“During the period we also secured 37 new approvals further deepening our regulatory footprint in the ASEAN region”
What: Product Count: 35-38 products
“We have 35 or 38 products coming out from Kenya which again are our brands and this is what we want to launch by next Q1”
What: US Subsidiary Profitability: 80-90% recovery
“we have almost like recovered 80 to 90% of our investment, what we have done to our profits. Those profits have already been earned”
What: B2C revenue mix reached 13% vs 4% last year.
“our B2C business witnessed strong momentum, increasing from 4% to 13% with B2B accounting for the remaining 87%.”
What: Not Given → 18% to 20% by year-end
“our B2C business growth grew from 4% last year to 13% for H1 so we are still waiting for considerable growth from 13% to probably 18 to 20% before the end of this financial year.”
Earnings deceleration risks from management commentary
Trigger: Governments like the African Zazibona collaboration favor local manufacturing over imports.
Management view: Focusing on niche rare molecules and private markets rather than cutthroat government tenders.
Monitor: regulatory
Trigger: The company operates in 40+ countries, many with volatile currencies.
Management view: Not explicitly detailed on call, but focus is on high-margin products to absorb costs.
Monitor: fx
Key quotes from recent conference calls
“600+ B2C products in development, Targeting 200+ B2C launches and over 2,000 new product filings [Previous B2C Revenue Mix guidance]”
“we look at at least this year and a year to come after we are looking at 20 to 25% of our B2C to be around 25% in next 1.5 year. [Initiative: B2C Expansion]”
“we have entered Algerian market and initiated product registration activities a key step in expanding our presence in North Africa region. [Initiative: Algerian Market Entry]”
“manufacturers have certain cost advantages from the government to improve their local manufacturing leading to faster filing approvals as well as an additional cost advantage of around 25%. [Risk (regulatory): MEDIUM]”
Headline numbers from the latest earnings call
Revenue
₹400 Cr
Why: Growth was driven by solid progress and consistent execution across B2B and B2C segments, particularly in Latin America.
Consolidated revenue showed substantial growth while margins remained compressed due to the high-volume US distribution business.
EBITDA
₹27 Cr
Why: The margin profile is influenced by the US subsidiary, Espee, which operates a high-volume, low-margin RLD distribution model.
Consolidated EBITDA margins are significantly lower than standalone margins due to the US entity's 80% revenue contribution.
PAT
₹22 Cr
Why: Profit growth was supported by the revenue surge, though partially offset by the lower margin mix from the US acquisition.
PAT after minority interest stood at ₹17.5 Cr, reflecting a 34% year-on-year increase.
Other Highlights
• B2C business grew from 4% to 13% of total revenue mix.
• Standalone revenue reached ₹47 Cr with 31.56% EBITDA margins.
• Secured 37 new approvals in the ASEAN region during the period.
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
B2C Revenue Mix
13%
Why: Aggressive focus on branded sales through Relius Pharma subsidiaries in Bolivia and Guatemala.
US Subsidiary Revenue Share
80%
Why: The acquisition of Espee USA provides a high-volume RLD distribution base.
Standalone EBITDA Margin
31.56%
Why: Reflects the high-margin nature of the core emerging market export business.
B2C Segment Gross Margin
60-70%
Why: Branded products in private markets command premium pricing.
ASEAN Region New Approvals
37
Why: Deepening regulatory footprint in the ASEAN region.
Advanced/Niche Export Mix
95%
Why: Focus on complex formulations like tablets, injections, and inhalers.
B2B Segment EBITDA Margin
32-33%
Why: Legacy business margin profile for finished formulations.
Countries Reached
40+
Why: Global distribution network expansion.
Forward-looking targets from management for FY26
OPM Guidance
8–10%
Targeting PAT margin improvement
Guidance Changes
B2C Revenue Mix Target: Not Given → 18% to 20% by year-end
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 18, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Remus Pharmaceuticals Ltd's latest quarterly results (Sep 2025) show
Remus Pharmaceuticals Ltd's current PE ratio is 24.1x.
Remus Pharmaceuticals Ltd's price-to-book ratio is 2.6x.
Remus Pharmaceuticals Ltd's fundamental strength based on key financial ratios
Remus Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
Remus Pharmaceuticals Ltd's return ratios over recent years
Remus Pharmaceuticals Ltd's operating cash flow is positive (FY2025).
Remus Pharmaceuticals Ltd's current dividend yield is 0.15%.
Remus Pharmaceuticals Ltd's shareholding pattern (Mar 2026)
Remus Pharmaceuticals Ltd's promoter holding has increased recently.
Remus Pharmaceuticals Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Remus Pharmaceuticals Ltd has 6 key growth catalysts identified from recent earnings analysis
Remus Pharmaceuticals Ltd has 2 key risks worth monitoring
In Q2 FY26, Remus Pharmaceuticals Ltd's management highlighted
Remus Pharmaceuticals Ltd's management has provided the following forward guidance for FY26
Remus Pharmaceuticals Ltd's most important sub-sector-specific KPIs from the latest concall
Based on quantitative research signals, here is why Remus Pharmaceuticals Ltd may be worth studying
Remus Pharmaceuticals Ltd investment thesis summary:
Remus Pharmaceuticals Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
